Advances in the assessment and control of the effector functions of therapeutic antibodies (Q83335115)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Advances in the assessment and control of the effector functions of therapeutic antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Xu-Rong Jiang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

An Song

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Svetlana Bergelson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Thomas Arroll

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Bhavin Parekh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Kimberly May

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Shan Chung

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Robert Strouse

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Anthony Mire-Sluis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Mark Schenerman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

101-111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd3365

21 January 2020

exact match

0 references

cites work

CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications

1 reference

Antibodies to watch in 2010

31 March 2020

1 reference

Therapeutic antibodies for autoimmunity and inflammation

31 March 2020

1 reference

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

31 March 2020

1 reference

FcgammaR: The key to optimize therapeutic antibodies?

31 March 2020

1 reference

Fcgamma receptors as regulators of immune responses

31 March 2020

1 reference

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

31 March 2020

1 reference

Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice

31 March 2020

1 reference

Engineered antibody Fc variants with enhanced effector function

31 March 2020

1 reference

From the bench to the bedside: ways to improve rituximab efficacy.

31 March 2020

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

31 March 2020

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

31 March 2020

1 reference

Engineered antibodies with increased activity to recruit complement

31 March 2020

1 reference

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

31 March 2020

1 reference

FcRn: the neonatal Fc receptor comes of age.

31 March 2020

1 reference

Antibody therapeutics: isotype and glycoform selection

31 March 2020

1 reference

Glycosylation as a strategy to improve antibody-based therapeutics

31 March 2020

1 reference

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

31 March 2020

1 reference

Expression systems for therapeutic glycoprotein production.

31 March 2020

1 reference

Glycosylation of recombinant antibody therapeutics

31 March 2020

1 reference

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

31 March 2020

1 reference

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

31 March 2020

1 reference

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

31 March 2020

1 reference

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

31 March 2020

1 reference

Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro

31 March 2020

1 reference

Post-translational modifications differentially affect IgG1 conformation and receptor binding.

31 March 2020

1 reference

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

31 March 2020

1 reference

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

31 March 2020

1 reference

Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.

31 March 2020

1 reference

Engineering therapeutic monoclonal antibodies.

31 March 2020

1 reference

Molecular engineering and design of therapeutic antibodies

31 March 2020

1 reference

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

31 March 2020

1 reference

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

31 March 2020

1 reference

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

31 March 2020

1 reference

The effect of Fc glycan forms on human IgG2 antibody clearance in humans

31 March 2020

1 reference

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types

31 March 2020

1 reference

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys

31 March 2020

1 reference

Isotype selection in antibody engineering

31 March 2020

1 reference

Antibody targeted drugs as cancer therapeutics

31 March 2020

1 reference

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

31 March 2020

1 reference

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

31 March 2020

1 reference

A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.

31 March 2020

1 reference

Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis

31 March 2020

1 reference

Measurement of cytotoxicity by target cell release and retention of the fluorescent dye bis-carboxyethyl-carboxyfluorescein (BCECF)

31 March 2020

1 reference

Cytotoxicity assays using cryopreserved target cells pre-labeled with the fluorescent marker europium

31 March 2020

1 reference

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

31 March 2020

1 reference

Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo

31 March 2020

1 reference

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

31 March 2020

1 reference

Utilization of Complement-Dependent Cytotoxicity To Measure Low Levels of Antibodies: Application to Nonstructural Protein 1 in a Model of Japanese Encephalitis Virus

31 March 2020

1 reference

Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines

31 March 2020

1 reference

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

31 March 2020

1 reference

Complement protein C1q recognizes a conformationally modified form of the prion protein.

31 March 2020

1 reference

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

31 March 2020

1 reference

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

31 March 2020

1 reference

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

31 March 2020

1 reference

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

31 March 2020

1 reference

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins

31 March 2020

1 reference

On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies

31 March 2020

1 reference

Differences in binding and effector functions between classes of TNF antagonists

31 March 2020

1 reference

IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21283105

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD3365

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21283105%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference